

Kohei Hashimoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7599311/publications.pdf>

Version: 2024-02-01

19
papers

182
citations

1163117

8
h-index

1125743

13
g-index

22
all docs

22
docs citations

22
times ranked

230
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome analysis for conservative management of Peyronie's disease. <i>International Journal of Urology</i> , 2006, 13, 244-247.	1.0	27
2	The correlation between metastasis-free survival and overall survival in non-metastatic castration resistant prostate cancer patients from the Medical Data Vision claims database in Japan. <i>Current Medical Research and Opinion</i> , 2019, 35, 1745-1750.	1.9	20
3	Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. <i>Cancer Science</i> , 2021, 112, 1524-1533.	3.9	19
4	Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 485-491.	1.6	18
5	Serum Testosterone Level to Predict the Efficacy of Sequential Use of Antiandrogens as Second-line Treatment Following Androgen Deprivation Monotherapy in Patients with Castration-resistant Prostate Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 405-410.	1.3	16
6	Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 8579-8588.	2.8	14
7	Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancer. <i>BJUI Compass</i> , 2020, 1, 165-173.	1.3	11
8	Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era. <i>International Journal of Urology</i> , 2022, 29, 647-655.	1.0	11
9	Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 934-941.	1.3	8
10	Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer. <i>Cancer Science</i> , 2021, 112, 3616-3626.	3.9	8
11	Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer. <i>Cancer Science</i> , 2022, 113, 2386-2396.	3.9	8
12	Incidence and risk factors of parastomal hernia after ileal conduit diversion in Japanese population. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1830-1834.	2.2	4
13	Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden. <i>International Journal of Urology</i> , 2022, , .	1.0	4
14	A case of metastatic Xp11.2 translocation renal cell carcinoma showing a prolonged response to nivolumab as 6th-line treatment. <i>International Cancer Conference Journal</i> , 2022, 11, 134-137.	0.5	3
15	Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	3
16	Long-term tadalafil administration can prevent functional and structural changes of the urinary bladder in male rats with partial bladder outlet obstruction. <i>Neurourology and Urodynamics</i> , 2020, 39, 1330-1337.	1.5	2
17	Management of hydronephrosis after radical cystectomy and urinary diversion for bladder cancer: A single tertiary center experience. <i>International Journal of Urology</i> , 2022, 29, 1046-1053.	1.0	2
18	Evaluation of the urethral $\hat{I} \pm \hat{I}^2$ ratio and tissue repair half-time for iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy. <i>Brachytherapy</i> , 2020, 19, 290-297.	0.5	1

#	ARTICLE	IF	CITATIONS
19	Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study. International Journal of Urology, 0, , .	1.0	1